Cerus Corporation (NASDAQ: CERS) today announced financial results for the third quarter and nine months ended September 30, 2013.
“This past quarter, we continued to submit INTERCEPT plasma and platelet PMA modules on schedule, and look forward to completing these submissions in November 2013 and March 2014, respectively,” said William ‘Obi‘ Greenman, Cerus‘ president and chief executive officer. “Our $10.5 million in Q3 product revenue provides steady progress toward our projected full year revenue guidance of $41-$43 million.”
Help employers find you! Check out all the jobs and post your resume.
